South Korean biopharmaceutical company Samsung Biologics said Wednesday that the company achieved a stellar performance last year to stand shoulder to shoulder with top global pharmaceutical companies, buoyed by an array of large contract manufacturing deals. The company has been ranked in 37th place in market research company GlobalData’s list of the world's top 50 pharmaceutical companies in 2022, up 13 .
The big pharma company Bristol Myers Squibb (BMS) has recruited contract manufacturing and development organization (CDMO) Samsung Biologics to manufacture a commercial antibody cancer treatment until 2030.
Samsung Biologics signed a $242 million contract manufacturing organization (CMO) deal with global pharmaceutical giant Bristol-Myers Squibb for the production of immuno-oncology drugs, the drug manufacturer said Monday. Samsung said the production agreement was made with BMS subsidiary Swords Laboratories. Under the contract, its Plant 4 will serve as the production base for BMS flagship immuno-oncology product for the next seven years through 2030.
Samsung Biologics said Monday that the company signed a $242 million contract manufacturing deal with Bristol-Myers Squibb subsidiary Swords Laboratories to produce immunotherapy treatments until 2030. Under the latest contract, Samsung Biologics will produce the flagship immunotherapies of BMS at the company’s fourth plant over the next seven years. BMS, the world's seventh-largest biopharmaceutical compa.